BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Asia Pacific on the Brink of a Healthcare Transformation with the Arrival of the Precision Era

The Precision Era of medicine is arriving in Asia Pacific, driven by the arrival of a critical mass of innovative therapies that will redefine treatment, a...

July 22, 2025 | News

How Ethical Gaps in Psychiatry Could Undermine Biopharma Progress

While innovation drives progress, the absence of consistent ethical safeguards in psychiatry can distort research outcomes and undermine clinical trials. S...

July 21, 2025 | News

BioPharma in APAC: Mid-Year Report 2025 – Tracking Progress, Trends & Possibilities Ahead

As we cross the midpoint of 2025, BioPharma APAC presents this Mid-Year Report—an incisive look at emerging biopharmaceutical dynamics, key i...

July 21, 2025 | Analysis

Using NLP-Driven Decision Support in Emergency Health Assistance

According to the US Department of Transportation, over 40,000 lives were lost in roadway deaths in 2023. The CDC reports that the country saw appro...

July 14, 2025 | News

FDA Publishes First-Ever Public Database of Complete Response Letters (2020–2024) – Now Available for Download

Download Approved CRLs – 2020 to 2024 (external link) U.S. Food and Drug Administration (FDA) has, for the first time, made pub...

July 14, 2025 | Regulatory

No More Whisper Networks: FDA Puts Its Rejection Reasons in Writing — Publicly

FDA Embraces Radical Transparency by Publishing Complete Response Letters For Immediate Release: July 10, 2025 &nb...

July 11, 2025 | News

FDA’s Most Recent 100 Warning Letters of 2025 Signal Rising Compliance Risks Across Pharma, Biologics, Devices, Food, and Online Markets

As of July 2025, the U.S. Food and Drug Administration (FDA) has issued over 3,400 warning letters, with the most recent 100 painting a vivid pictu...

July 11, 2025 | Analysis | By BioPharma APAC Desk

FDA Finalises Guidance on Drug Development for Early Lyme Disease: A Strategic Signal for Industry Innovation

This finalised guidance serves as a blueprint for biopharmaceutical developers aiming to address early manifestations of Lyme disease—particularly ea...

July 11, 2025 | Analysis | By BioPharma APAC Desk

The Role of Unique Device Identification (UDI) in Tracing Medical Device Safety

According to GlobeNewswire, this vital sector is projected to reach an impressive $756.59 billion by 2031, exhibiting a CAGR of 5.8% from 2024 to 2031. How...

July 02, 2025 | Report

Southeast Asia Poised to Lead AI-Driven Healthcare Transformation Amid Rising Cross-Border Collaboration

The Southeast Asia (SEA) region’s role in healthcare innovation, long bolstered by Singapore’s commitment to serve as a g...

July 01, 2025 | Opinion | By Chu Canh Chieu, FPT Software Managing Director of Global Healthcare Center, FPT Corporation

Innovent Biologics Secures NMPA Approval for World’s First Dual GCG/GLP-1 Receptor Agonist Mazdutide for Weight Management in China

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality me...

June 30, 2025 | News